Related Experiment Video
Updated: Feb 7, 2026

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
Published on: July 26, 2022
Mesenchymal stem cell exosomes alleviate ischemic myocardial injury by miR-125b-5p/BTG2 pathway
Lijun Luo1,2, Lieyou Li1,3, Shuyun Wu1,2
1Department of Cardiology, Fujian Cardiovascular Medical Center, Fujian Institute of Coronary Artery Disease, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Abstract:
MicroRNAs mediate the protective effects of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) against myocardial injury. This study aimed to elucidate the specific role of exosomal miR-125b-5p in ischemic myocardial injury, focusing on its regulatory interaction with B-cell translocation gene 2 (BTG2). Murine BMSCs were transfected with miR-125b-5p inhibitor or negative-control (NC) oligonucleotides and then used to generate miR-125b-5p-knockdown (miR-125b-5pKD)-Exos or NC-Exos under hypoxic condition. In vivo, myocardial infarction (MI) was induced by LAD ligation, followed by intramyocardial injection with 50 μl of PBS, or containing 200 μg of NC-Exos, or miR-125b-5pKD-Exos. In vitro, HL-1 cells were treated with NC-Exos or miR-125b-5pKD-Exos at a final concentration of 50 μg/ml under hypoxia/serum-deprived (HSD) condition. Cell apoptosis, inflammation, fibrosis, cardiac function and BTG2 expression were assessed. Exosomes uptake was detected by fluorescence microscopy after exosomes labeled with DiD dye were injected into ischemic myocardium or co-cultured with HL-1 cells under HSD condition. Dual-luciferase reporter assay was applied to validate miR-125b-5p/BTG2 interaction. When compared with group MI, treatment with NC-Exos significantly alleviated the inflammatory response (inflammation score: 1.70 ± 0.37 vs. 3.47 ± 0.22, P < 0.01), inhibited cardiac fibrosis (fibrotic area ratio: 15.98% ± 2.79% vs. 31.55% ± 3.54%, P < 0.01), and improved cardiac function (ejection fraction: 49.48% ± 6.43% vs. 29.35% ± 5.79%, P < 0.01 and fractional shortening: 30.88% ± 3.70% vs. 16.15 ± 2.72%, P < 0.01). NC-Exos reduced the cell apoptosis by 41.5% in vivo (18.00% ± 3.74% vs. 30.75% ± 3.86%, P < 0.01) when compared with group MI and by 52.2% in vitro (10.48% ± 1.80% vs. 21.93% ± 1.76%, P < 0.001) when compared with group HSD. Treatment with NC-Exos also resulted in remarkable down-regulation of BTG2 expression. The knockdown of miR-125b-5p weakened these protective effects of NC-Exos. The effective uptake of DiD-labeled exosomes by ischemic myocardium and HL-1 cells were confirmed by fluorescence microscopy. Dual-luciferase reporter assay further confirmed that BTG2 is the target of miR-125b-5p. BMSC-derived exosomes confer cardioprotection, at least in part, by transferring miR-125b-5p into cardiomyocytes to target BTG2.
Insights
Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) protect the heart by delivering miR-125b-5p, which targets BTG2 to reduce myocardial injury. This microRNA transfer alleviates inflammation, fibrosis, and apoptosis, improving cardiac function after ischemic events.
Area of Science:
- Cardiovascular Biology
- Stem Cell Biology
- Molecular Medicine
- Exosome Biology
Background:
- Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) exhibit cardioprotective properties against myocardial injury.
- MicroRNAs (miRNAs) are key mediators of these protective effects, but specific miRNAs and their targets remain to be fully elucidated.
- Exosomal miR-125b-5p is investigated for its role in ischemic myocardial injury and its interaction with B-cell translocation gene 2 (BTG2).
Purpose of the Study:
- To determine the specific role of exosomal miR-125b-5p in mitigating ischemic myocardial injury.
- To investigate the regulatory interaction between miR-125b-5p and its target gene, BTG2.
- To assess the therapeutic potential of BMSC-Exos carrying miR-125b-5p in a myocardial infarction model.
Main Methods:
- Murine BMSC transfection to generate miR-125b-5p-knockdown (KD) exosomes and control exosomes.
- In vivo study: Myocardial infarction (MI) induced in mice, followed by intramyocardial injection of PBS, control exosomes, or miR-125b-5pKD-Exos.
- In vitro study: HL-1 cells treated with exosomes under hypoxia/serum-deprived (HSD) conditions.
- Assessment of apoptosis, inflammation, fibrosis, cardiac function, and BTG2 expression.
- Exosome uptake confirmed by fluorescence microscopy using DiD-labeled exosomes.
- Dual-luciferase reporter assay to validate the miR-125b-5p/BTG2 interaction.
Main Results:
- Control exosomes significantly alleviated inflammatory response, inhibited cardiac fibrosis, and improved cardiac function (ejection fraction and fractional shortening) in MI mice compared to PBS.
- Control exosomes reduced cardiomyocyte apoptosis both in vivo and in vitro.
- Treatment with control exosomes led to down-regulation of BTG2 expression.
- Knockdown of miR-125b-5p in exosomes attenuated these protective effects.
- Dual-luciferase assay confirmed BTG2 as a direct target of miR-125b-5p.
- DiD-labeled exosomes were effectively taken up by ischemic myocardium and HL-1 cells.
Conclusions:
- BMSC-Exos exert cardioprotective effects against ischemic myocardial injury.
- Exosomal miR-125b-5p plays a crucial role in mediating these protective effects by targeting BTG2.
- BMSC-Exos transfer miR-125b-5p to cardiomyocytes, thereby reducing apoptosis, inflammation, and fibrosis, and improving cardiac function.
Related Concept Videos
Mesenchymal Stem Cells
Adult Stem Cells
Embryonic Stem Cells
Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Induced Pluripotent Stem Cells

